Capecitabine Market: Industry Analysis and Forecast 2023-202: By Indication, Distribution Channel, and Region

Capecitabine Market is anticipated to reach US$ 2.99 Bn by 2029 from US$ 0.61 Bn in 2022 at a CAGR of 6.2 % during a forecast period.

Capecitabine is a prodrug that operates as a nucleoside metabolic inhibitor. The chemical is transformed into fluorouracil, which inhibits DNA synthesis and slows cancer cell development. It's taken orally and is authorized to treat a variety of tumors, including metastatic colorectal cancer, breast cancer, and others.

The report provides a comprehensive analysis and reliable revenue data for the player from 2021 to 2027. It also includes comprehensive forecasts for the years 2021-2027, based on accurate revenue data (global and regional). Company description, main business, total income and sales, revenue earned in the market, date of debut in the market, product launch, current developments, and other facts are provided.



To know about the Research Methodology:-Request Free Sample Report

In the report, 2021 is considered a base year however 2021’s numbers are on the real output of the companies in the market. Special attention is given to 2021 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done well in lockdown also and a specific strategic analysis of those companies is done in the report.
Capecitabine Market Dynamics
The increased demand for capecitabine can be ascribed to its antimetabolite action, which operates by interfering with DNA synthesis and so reducing the severity of side effects. Besides, the global burden of cancer and tumor patients is expected to fuel the market. According to the World Health Organization, cancer is the biggest cause of death globally, with approximately 9.6 million deaths projected in 2022. Additionally, breast cancer claimed the lives of 627,000 women worldwide, accounting for nearly 15% of all cancer fatalities among women. In addition, a sharp increase in healthcare spending, as well as continued R&D initiatives in cancer therapy, are projected to open up new market opportunities.

In addition, rising awareness initiatives by governments and private organizations such as Cancer Care, Cancer Research UK, and Cancer Suraksha Scheme are expected to move the global capecitabine market forward throughout the forecast period.

Restraints: The global capecitabine market is being held back by a variety of adverse effects connected with the drug. Anemia, chest discomfort, diarrhea, vomiting, weakness, blood clotting disorders, and cardiac-related concerns such as cardiomyopathy are all major adverse effects of the medicine. Other common contraindications include kidney illness, DPD deficiency, and pregnancy.

The Breast Cancer Segment Is Expected To Account For The Largest Share of xx% By 2029.

The segment’s dominance can be ascribed to increased prescriptions as the gold standard for breast cancer treatment due to its established efficacy. Additionally, its benefits, such as increased accessibility and availability in the form of an oral dose, have improved patient convenience. Increased prescriptions of capecitabine in combination with docetaxel, pertuzumab, and trastuzumab to prolong overall survival in metastatic breast cancer are also expected to fuel the segment's growth throughout the forecast period.

North America Dominated the Capecitabine Market With xx% Of The Market Share In 2021.

The region's domination is attributable to the increased occurrence of cancers such as colorectal cancer and colon cancer. Physical inactivity, obesity, stress, and a sedentary lifestyle are all contributing causes to rising cancer rates. Furthermore, a sharp increase in the older population in the United States owing to the presence of baby boomers during the predicted period leads to increased income for the region. As a result, the market is fuelled by a large target audience and growing disposable income in the United States. Besides, the existence of important manufacturers performing cancer clinical studies, such as Roche, Teva, and others, is expected to contribute to the global capecitabine market's considerable revenue share.

Considering continuous capecitabine research and development, Europe is the second-largest market. Because of the presence of major generic pharmaceutical firms in Asia-Pacific, as well as an increase in government efforts and special communities, the market for capecitabine is expected to grow rapidly.

Competitive Landscape

There are many main competitors in the global capecitabine market, which is relatively competitive. Most Capecitabine enterprises work with a feeling of urgency and a consumer focus in the post-pandemic age. Efforts to reduce costs across the value chain in order to offer products at competitive pricing. Additionally, long-term success will be determined by continuing innovation and customer-focused tactics, as well as upgrading and expanding production. The report provides high-quality data and analysis to assist decision-makers in developing solid business strategies.

Few of the market's major players are employing different methods such as purchasing items or other businesses to strengthen their market positions throughout the world, while others are creating new markets. For example, Armas Pharmaceuticals, Inc introduced a generic version of Roches' capecitabine medication Xeloda in April 2019. The market is likely to increase as a result of such product releases.

Seattle Genetics received FDA clearance for its TUKYSA (Tucatinib) tablets for breast cancer in April 2020. TUKYSA, a tyrosine kinase inhibitor, is used in combination with Roche's capecitabine and trastuzumab to treat metastatic HER2-positive breast cancer.

Following FDA clearance, Dr. Reddy's Laboratories introduced Capecitabine Tablets, USP, a therapeutic generic version of Xeloda Tablets, in February 2021.

Report Objectives:

• To give a complete study of the global Capecitabine market structure, as well as forecasts for the main segments and sub-segments.

• To give information on the elements that influence market growth. Price analysis, supply chain analysis, Porte five force analysis, and other aspects will be used to study the Capecitabine market.

• To give historical and future revenue for market segments and sub-segments in four major geographies and countries: North America, Europe, Asia, Latin America, and the Rest of the World.

• To give a country-level market study in terms of current market size and future prospects.
The report also helps in understanding the Capecitabine Market dynamics, and structure by analyzing the market segments to project the Capecitabine Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Capecitabine Market make the report investor’s guide.
Capecitabine Market Scope: Inquire before buying



Capecitabine Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
US $ 0.61 Bn.


Forecast Period 2023 to 2029 CAGR:
6.2%
Market Size in 2029:
US $ 2.99 Bn.


 Segments Covered:
by Indication
• Colorectal Cancer
• Breast Cancer
• Others


by Distribution Channel
• Hospitals
• Clinical Laboratories
• Others



Capecitabine Market, by Region
• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)
Capecitabine Market by Region
• North America
• Europe
• Asia pacific
• The Middle East and Africa
• South America
Capecitabine Market: Key Players
• Fresenius SE & Co. KGaA
• Genentech, Inc.
• Dr Reddy Laboratories Ltd.
• Cipla Inc.
• Accord Healthcare Ltd.
• F. Hoffmann-La Roche Ltd.
• Teva Pharma B.V., Sandoz Inc.
• Zentiva N.V.
• Ranbaxy Laboratories Ltd.
• Roche
• Mylan
• Hikma
• Hengrui Medicine
• Reliance Group
• Hetero
• Sandoz
• Novartis AG
• Sensus healthcare
• RXi Pharmaceuticals, Inc.
• Perrigo Company PLC
• Pacific World Corporation
• Revitol Corporation
• Avita Medical Limited

Frequently Asked Questions:

1. Which region has the largest share in Global Capecitabine Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Capecitabine Market?
Ans: The Global Capecitabine Market is growing at a CAGR of 6.2% during forecasting period 2023-2029.

3. What is scope of the Global Capecitabine Market report?
Ans: Global Capecitabine Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Capecitabine Market?
Ans: The important key players in the Global Capecitabine Market are – Fresenius SE & Co. KGaA, Genentech, Inc., Dr Reddy Laboratories Ltd., Cipla Inc., Accord Healthcare Ltd., F. Hoffmann-La Roche Ltd., Teva Pharma B.V., Sandoz Inc., Zentiva N.V., Ranbaxy Laboratories Ltd., Roche, Mylan, Hikma, Hengrui Medicine, Reliance Group, Hetero, Sandoz, Novartis AG, Sensus healthcare, RXi Pharmaceuticals, Inc., Perrigo Company PLC, Pacific World Corporation, Revitol Corporation, and Avita Medical Limited

5. What is the study period of this Market?
Ans: The Global Capecitabine Market is studied from 2022 to 2029.